Cargando…
Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome
Background: The C5 complement inhibitor eculizumab is first-line treatment in atypical hemolytic uremic syndrome (aHUS) going along with a highly increased risk of meningococcal infections. Serogroup B meningococci (MenB) are the most frequently encountered cause for meningococcal infections in Euro...
Autores principales: | Mülling, Nils, Rohn, Hana, Vogel, Ulrich, Claus, Heike, Wilde, Benjamin, Eisenberger, Ute, Kribben, Andreas, Witzke, Oliver, Gäckler, Anja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098122/ https://www.ncbi.nlm.nih.gov/pubmed/32159209 http://dx.doi.org/10.1042/BSR20200177 |
Ejemplares similares
-
Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients
por: Gäckler, Anja, et al.
Publicado: (2021) -
Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants
por: Gäckler, Anja, et al.
Publicado: (2019) -
Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation
por: Lindemann, Monika, et al.
Publicado: (2021) -
Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci
por: Stinson, C., et al.
Publicado: (2020) -
Atypical hemolytic uremic syndrome
por: Loirat, Chantal, et al.
Publicado: (2011)